Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

APPLICATION OF PREPARATIVE HIGH-SPEED COUNTERCURRENT CHROMATOGRAPHY FOR SEPARATION OF ELATINE FROM DELPHINIUM SHAWURENSE.

Journal of liquid chromatography & related technologies·2011

Same author

[Endothelial progenitor cells in acute lung injury].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases·2011

Same author

[Overview of weaning-induced acute cardiac dysfunction].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases·2011

Same author

Sulfur oxidation activities of pure and mixed thermophiles and sulfur speciation in bioleaching of chalcopyrite.

Bioresource technology·2011

Same author

Salivary testosterone levels and autism-spectrum quotient in adults.

Neuro endocrinology letters·2011

Same author

Posterior reversible encephalopathy syndrome associated with nephrotic syndrome.

Neuro endocrinology letters·2011

Search research articles

Related Experiment Video

Updated: May 21, 2026

The Efficacy and Underlying Pathway Mechanisms of ShiDuGao Treatment for Anus Eczema Based on GEO Datasets and Network Pharmacology

The Efficacy and Underlying Pathway Mechanisms of ShiDuGao Treatment for Anus Eczema Based on GEO Datasets and Network Pharmacology

Published on: January 12, 2024

Efficacy and safety of biologics for eosinophilic granulomatosis with polyangiitis: a network meta-analysis.

Yuling Zhang¹, Yi Yang¹

¹Department of Otolaryngology, Beijing Hospital, National Center of Gerontology, National Clinical Research Center for Gerontology, The Key Laboratory of Geriatrics of NHC, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China.

Postgraduate Medicine

|May 20, 2026

Summary

Benralizumab and mepolizumab show promise in achieving remission and reducing oral corticosteroid (OCS) use for eosinophilic granulomatosis with polyangiitis (EGPA). These biologics demonstrated safety profiles comparable to conventional therapies.

Keywords:

Biologics efficacy eosinophilic granulomatosis with polyangiitis network meta-analysis safety

Related Experiment Videos

Last Updated: May 21, 2026

The Efficacy and Underlying Pathway Mechanisms of ShiDuGao Treatment for Anus Eczema Based on GEO Datasets and Network Pharmacology

The Efficacy and Underlying Pathway Mechanisms of ShiDuGao Treatment for Anus Eczema Based on GEO Datasets and Network Pharmacology

Published on: January 12, 2024

Area of Science:

Rheumatology
Immunology
Pharmacology

Background:

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic vasculitis impacting small-to-medium vessels.
Eosinophil infiltration and granulomas characterize EGPA, affecting multiple organs.
Biologics offer potential therapeutic advancements for EGPA management.

Purpose of the Study:

To conduct a network meta-analysis comparing the efficacy and safety of biologics in adult EGPA patients.
To evaluate remission rates, oral corticosteroid (OCS) dosage, and relapse rates associated with different biologics.
To assess the safety profiles of biologics versus conventional therapy in EGPA.

Main Methods:

Systematic literature search across major databases (PubMed, EMBASE, Cochrane, Web of Science, ClinicalTrials.gov).
Network meta-analysis using a random-effects model, adhering to PRISMA guidelines.
Comparison of primary (remission rate) and secondary outcomes (OCS dose, relapse rate), including adverse events (AEs).

Main Results:

Seventeen studies with 1150 participants evaluated four biologics: mepolizumab, benralizumab, rituximab, and omalizumab.
Benralizumab and mepolizumab significantly improved remission rates compared to placebo.
Benralizumab and mepolizumab (300mg) effectively reduced OCS dosage and prevented relapses, with comparable overall and serious AE rates to conventional therapy.

Conclusions:

Benralizumab and mepolizumab demonstrate potential for inducing clinical remission and reducing OCS dependence in EGPA.
These biologics exhibit favorable safety profiles, similar to placebo, for EGPA patients.
Further research may solidify the role of benralizumab and mepolizumab in EGPA treatment algorithms.